Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 2, 2000, Pages 200-204

  Sundar, Shyam ^a   Gupta, Lal B ^a   Rastogi, Vishal ^a   Agrawal, Gaurav ^a   Murray, Henry W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Amphotericin B fat emulsion; Chemotherapy; Health costs; India; Kala azar; Leishmania donovani; Visceral Leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ANTIMONY; LIPID EMULSION; LIPOLIPID;

ADOLESCENT; ADULT; ARTICLE; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; FEMALE; FEVER; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; SPLEEN; VISCERAL LEISHMANIASIS;

LEISHMANIA DONOVANI; NASO HEXACANTHUS; PROTOZOA;

EID: 0034110123     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90277-3     Document Type: Article

References (30)

1. Berman, J. D. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases, 24, 684-703.
2. Berman, J. D., Badaro, R., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R., Kuzoe, F., Pang, L., Weerasuriya, K. & Bryceson, A. D. M. (1998). Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of the World Health Organization, 76, 25-32.
3. Chavanet, P. Y., Garry, I., Charlier, N., Caillot, N., Kisterman, J.-P., D'Athis, M. & Portier, H. (1992). Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. British Medical Journal, 305, 921-925.
4. Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Russo, R., Graeta, G. B., Pempinello, R., Scotti, S., Raimondi, F., Cascio, A., Prestileo, T., Caldeirs, L., Wilkinson, R. J. & Bryceson, A. D. M. (1994). Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Quarterly Journal of Medicine, 87, 75-81.
5. Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Gaeta, G. B., Pempinello, R., Scotti, S., Cascio, A., Castagnola, E., Maisto, A., Gramiccia, M., di Caprio, D., Wilkinson, R. J. & Bryceson, A. D. M. (1996). Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases, 22, 938-943.
6. Dietze, R., Fagundes, S. M. S., Brito, E. F., Milan, E. P., Feitosa, T. F., Suassuna, F. A. B., Fonschiffrey, G., Ksionski, G. & Dember, J. (1995). Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 309-311.
7. Di Martino, L., Davidson, R. N., Giacchino, R., Scotti, S., Raimondi, F., Castagnola, E., Tasso, L., Cascio, A., Gradoni, L., Gramiccia, M., Pettoello-Mantovani, M. & Bryceson, A. D. M. (1997). Treatment of visceral leishmaniasis in children with liposomal amphotericin B. Journal of Pediatrics, 131, 271-277.
8. Freire, M., Badaro, F., Avelar, M. E., Luz, K., Nakatani, M. S., Teixeira, R., Netto, E. M. & Badaro, R. (1997). Efficacy and tolerability of liposomal amphotericin B (AmBisome) in the treatment of visceral leishmaniasis in Brazil. Brazilian Journal of Infectious Diseases, 1, 230-240.
9. Giri, O. P. (1994). Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B. Journal of the Association of Physicians of India, 42, 688-689.
10. Gradoni, L., Bryceson, A. & Desjeux, P. (1995). Treatment of Mediterranean visceral leishmaniasis. Bulletin of the World Health Organization, 73, 191-197.
11. Herbrecht, R., Sosa, C., Himy, R. & Villard, O. (1996). Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report. Transactions of the Royal Society of Tropical Medicine and Hygiene, 90, 322-323.
12. Herbrecht, R. & Letscher, V. (1997). Safety and efficacy of Intralipid emulsions of amphotericin B [Letter]. Journal of Antimicrobial Chemotherapy, 40, 137-139.
13. Jha, T. K., Giri, Y. N., Singh, T. K. & Jha, S. (1995). Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. American Journal of Tropical Medicine and Hygiene, 52, 536-538.
14. Jha, T. K., Olliaro, P., Thakur, C. P. N., Kanyok, T. P., Singhania, B. L., Singh, I. J., Singh, N. P. K., Akhoury, S. & Jha, S. (1998). Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in north Bihar, India. British Medical Journal, 361, 1200-1205.
15. Mishra, M., Biswas, U. K., Jha, D. N. & Khan, A. B. (1992). Amphotericin B versus pentamidine in antimony-unresponsive kala-azar. Lancet, 340, 1256-1257.
16. Mishra, M., Biswas, U. K., Jha, A. M. & Khan, A. B. (1994). Amphotericin B versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet, 344, 1599-1600.
17. Petit, N., Parola, P., Dhiver, C. & Gastaut, J.-A. (1996). Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients [Letter]. Journal of Antimicrobial Chemotherapy, 38, 154-157.
18. Seaman, J., Boer, C., Wilkinson, R., de Jong, J., de Wielde, E. & Davidson, R. (1995). Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clinical Infectious Diseases, 21, 188-193.
19. Sievers, T. M., Kubak, B. M. & Wong-Beringer, A. (1996). Safety and efficacy of Intralipid emulsions of amphotericin B. Journal of Antimicrobial Chemotherapy, 38, 333-347.
20. Sundar, S. (1997). Treatment of visceral leishmaniasis - current status. Journal of the Association of Physicians of India, 45, 640-647.
21. Sundar, S. & Murray, H. W. (1996). Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. Journal of Infectious Diseases, 173, 762-765.
22. Sundar, S., Agrawal, N. K., Sinha, P. R., Horwith, G. S. & Murray, H. W. (1997a). Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine, 127, 133-137.
23. Sundar, S., Singh, V. P., Sharma, S., Makharia, M. K. & Murray, H. W. (1997b). Response to interferon-y plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases, 176, 1117-1119.
24. Sundar, S., Goyal, A. K., More, D. K., Singh, M. K. & Murray, H. W. (1998a). Ultra-short-course amphotericin B lipid complex treatment for antimony-unresponsive Indian visceral leishmaniasis. Annals of Tropical Medicine and Parasitology, 92, 755-764.
25. Sundar, S., Rosenkaimer, F., Makharia, M. K., Voss, A., Hilgard, P. & Murray, H. W. (1998b). Trial of oral miltefosine for visceral leishmaniasis. Lancet, 352, 1821-1823.
26. Sundar, S., Goyal, A. K., Manda, I. A. K., Makharia, M. K., Singh, V. P. & Murray, H. W. (1999). Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis. Journal of the Association of Physicians of India, 47, 186-188.
27. Thakur, C. P. (1994). Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 698-699.
28. Thakur, C. P., Sinha, G. P., Barat, D. & Singh, R. K. (1994). Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Annals of Tropical Medicine and Parasitology, 88, 365-370.
29. Thakur, C. P., Pandey, A. K., Sinha, G. P., Roy, S., Behbehani, K. & Olliaro, P. (1996). Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 90, 319-322.
30. Thakur, C. P., Sinha, G. P., Pandey, A. K., Kumar, N., Kumar, P., Hassan, S. M., Narain, S. & Roy, R. K. (1998). Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Annals of Tropical Medicine and Parasitology, 92, 561-569.